Supporting smoking cessation for people with COPD

For people with chronic obstructive pulmonary disease (COPD), community-based support for smoking cessation is more than a respiratory clinic add-on. It brings together treatment, behaviour change and the practical conditions that shape a person's ability to stop. The 2023 APEC Conference on Promoting Community-based Non-Communicable Diseases Integrated Care Model offers a relevant lens: chronic lung disease is supported across homes, workplaces and neighbourhoods, alongside hospital care. Learn more about リウマチ性疾患の患者報告アウトカム Pro を用いた診察の進め方.

Smoking remains the leading modifiable environmental risk for COPD. Stopping slows the loss of lung function, while continued smoking increases the likelihood of exacerbations, admissions and impaired daily activity. The message matters for older adults, who may have lived with smoking-related symptoms for decades and can still gain from support. Clinicians should present quitting as active treatment with a future, rather than as blame for past choices.

Tobacco dependence is not a test of willpower. Nicotine alters reward and withdrawal, while cues such as coffee breaks, stress and social occasions can sustain a habit that began long before a person developed COPD. Effective care therefore combines an appropriate cessation medicine with practical counselling, a clear quit plan and follow-up. It also asks what support is affordable, accessible and acceptable to the individual.

For community-based teams, the challenge is to make that pathway ordinary: a conversation at a GP visit, medicine available at a nearby pharmacy, a rehabilitation class that does not exclude people who still smoke, and a service that remains reachable after a lapse. The aim is not a single perfect attempt. It is repeated, coordinated help that allows people with COPD to remain as active and independent as possible.

Why stopping smoking changes the course of COPD

Smoking cessation has a greater effect on the long-term decline in lung function than any other single treatment available for COPD. This benefit is most pronounced when smoking stops early, but it remains meaningful at any stage of disease. A referral made during an acute admission can therefore become the start of long-term treatment rather than a discharge instruction.

The benefits extend beyond lung function. Reduced tobacco exposure can improve symptoms, exercise tolerance and recovery from illness, while also lowering cardiovascular risk and the burden of frequent exacerbations. People who smoke may attribute breathlessness entirely to damaged lungs, making it useful to explain that stopping can preserve capacity for walking, gardening, paid work or caring for family.

Care should begin with a respectful conversation about current smoking, previous quit attempts and the person's priorities. Ask whether they want help, then explore triggers such as alcohol, work stress or social rituals. A collaborative approach builds confidence without assuming that every person is ready on the same day. Listening should include what daily life feels like, not just cigarette counts. The patient-reported outcomes guidance developed in rheumatology illustrates how structured discussion of function and treatment burden can guide care; the same principle transfers well to COPD, where breathlessness and confidence in activity matter as much as spirometry.

A treatment plan people can use

Australian and international guidelines support varenicline, bupropion and nicotine replacement therapy as effective smoking-cessation treatments. A prescriber can match the medicine to dependence, comorbidities and previous experience, while a pharmacist or nurse can reinforce how to use it correctly. For stronger dependence, combining a short-acting and long-acting form of nicotine replacement may improve quit rates.

Behavioural support should sit alongside medicine, not wait until a quit date. Motivational interviewing can clarify ambivalence, and a practical plan can identify situations likely to trigger withdrawal. Agreeing on a date, removing cigarettes and supplies, and arranging support for the first difficult week make the intention more concrete. Withdrawal discomfort should be explained in advance, with options for adjusting treatment if needed.

Alongside local respiratory expertise, regional professional networks can support knowledge exchange. The APSR 2022 conference is one example of the wider communities through which clinicians compare approaches to long-term disease management. Cessation pathways still need local ownership, because medicine access, language, transport and trust determine whether a sound protocol becomes effective care.

Older adults need particular attention to safety and communication. Prescribers should review kidney function, other medicines, mood and sleep, and simplify the plan where possible. Teach-back is useful for both inhaler technique and the quit plan: the person explains the steps in their own words, allowing misunderstandings to be corrected while the consultation is still underway.

Australian pathways and everyday access

Access begins close to home. In Australia, nicotine replacement patches, gum and lozenges can be bought over the counter at pharmacies, while varenicline and bupropion require a prescription. Nicotine vapes marketed for cessation are supplied as prescription medicines under the national vaping framework. This differs from countries where vaping products are widely sold without a prescription and places a greater share of responsibility on clinicians and pharmacies.

Local availability still matters. In Melbourne and Sydney, apartment living and smoke-free hospitality areas make shared entrances, pavement dining and nearby workplaces common settings where smoking cues are visible. Clear building policies, well-signposted pharmacy services and support for residents who cannot easily travel can turn a difficult encounter into a practical route into care. Clinicians can also ask about the specific situations in which smoking is hardest to avoid.

For people in regional Queensland or outside capital cities, distance can be the first barrier. A local pharmacist, community nurse, telehealth clinician or visiting GP may provide options that a metropolitan patient takes for granted. The national Quitline, 13 QUIT (13 48QUIT), provides free telephone support, including when travel, work schedules or digital access make an appointment difficult.

Community partnerships that reach beyond clinics

Clinical prescribing becomes stronger when community networks reinforce it. A GP can send a warm referral to a pharmacist or Quitline; a pulmonary rehabilitation team can review tobacco use alongside exercise technique and inhaler use; and local councils can connect residents with cessation services. The pathway should work for someone who cannot queue for a specialist or attend during business hours.

A related resource on faith-based partnerships offers a useful example of how faith-based organisations can extend awareness and referral through trusted local networks. In Melbourne, Brisbane and other Australian cities, health information sessions and volunteer-led navigation can connect people with accredited cessation services. Clear boundaries are important so that supportive outreach never becomes unsafe treatment advice.

Partnerships must be reciprocal rather than extractive. In Aboriginal and Torres Strait Islander communities, tobacco use is shaped by colonisation, intergenerational stress and the history of tobacco industry promotion. Community-controlled health services can combine culturally safe cessation support with other priorities, such as housing, mental health and family wellbeing, without expecting people to separate smoking from the conditions that make dependence hard to manage.

Access should also account for language, disability, transport and digital confidence. Translated materials, telephone support and outreach through multilingual community workers can make the service usable for people who cannot easily navigate mainstream clinics. Community health workers can help with appointment bookings, medicine access and referrals to transport support.

Measuring progress while keeping care personal

Evaluation should track both reach and outcomes. Useful measures include the proportion of patients offered help, completed quit attempts, six- and twelve-month abstinence, and changes in breathlessness, activity and quality of life. Exacerbations and hospital use may improve over time, but they are influenced by many factors and should not be the sole measure of a cessation programme.

Operational data matter too: waiting times, referral completion, medicine availability and missed follow-ups. A referral is not a treatment plan until the patient has a medicine, an appointment and a way to manage withdrawal. Digital systems should support rather than replace human contact, and data collection should remain proportionate to the benefit for the patient.

Relapse is not discharge. People may smoke again after weeks of abstinence because illness, family stress or a return to an old routine has changed. Reviewing the trigger, renewing the plan and offering another attempt are part of good care. Weak programme results can likewise reveal a need for better outreach or supply, rather than justify withdrawing support.

Connecting smoking cessation with wider chronic care

Teams can revisit the conference agenda and resources to review the wider non-communicable disease agenda and the practical context for community-based care. Diabetes, obesity and cardiovascular conditions often coexist with COPD, and smoking cessation intersects with all three. It can reduce vascular risk and lessen the complications associated with diabetes, while also supporting physical activity that benefits weight, blood pressure and mood.

A respiratory assessment should therefore sit within a broader chronic-care plan. Alongside smoking-cessation support, teams can review spirometry, inhaler technique, influenza and pneumococcal vaccination, pulmonary rehabilitation and written action plans. People who still smoke may need rehabilitation adaptations, and a lower exercise tolerance should not be treated as proof that stopping will not help.

Coordinated records and shared goals reduce the burden of attending several disconnected programmes. A referral from a GP, respiratory nurse or pharmacist should appear in a common care plan, with consent respected and the patient's own priorities visible. This matters particularly for older adults managing several conditions, limited mobility or medication costs. One consistent offer of help is more valuable than several services repeating the same advice.

Communities can make this practical now. Health services can agree on a standard smoking-cessation offer, keep first-line medicines available, and establish warm referral pathways between primary care, pharmacies, rehabilitation and Quitline. Community organisations can provide culturally safe navigation and practical support, while councils can ensure information reaches people facing language, disability or housing barriers.

Each person with COPD who wants to stop deserves a clear plan, affordable treatment and a follow-up contact, not a leaflet alone. Build that pathway around their life, review it after setbacks and make every attempt count. Stopping smoking is one of the most direct ways to protect lung function, reduce future harm and support longer, more active lives in the community.